Safety, Tolerability and Preliminary Efficacy of Lenodiar Pediatric in Diarrhea
Klíčová slova
Abstraktní
Termíny
| Poslední ověření: | 04/30/2019 |
| První předloženo: | 07/01/2018 |
| Odhadovaná registrace vložena: | 07/22/2018 |
| První zveřejnění: | 07/25/2018 |
| Poslední aktualizace byla odeslána: | 05/30/2019 |
| Poslední aktualizace zveřejněna: | 06/03/2019 |
| Aktuální datum zahájení studie: | 09/30/2019 |
| Odhadované datum dokončení primární: | 11/30/2020 |
| Odhadované datum dokončení studie: | 02/28/2021 |
Stav nebo nemoc
Intervence / léčba
Device: Lenodiar Pediatric in Acute/Prolonged Diarrhea
Device: Lenodiar Pediatric in Chronic Diarrhea
Fáze
Skupiny zbraní
| Paže | Intervence / léčba |
|---|---|
| Experimental: Lenodiar Pediatric in Acute/Prolonged Diarrhea LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.
Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:
a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;
an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane. | Device: Lenodiar Pediatric in Acute/Prolonged Diarrhea 1 sack every 4 hours, maximum 4 sacks/day for 7 days. |
| Experimental: Lenodiar Pediatric in Chronic Diarrhea LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.
Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:
a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;
an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane. | Device: Lenodiar Pediatric in Chronic Diarrhea 1 sack every 4 hours, maximum 4 sacks/day for 28 days. |
Kritéria způsobilosti
| Věky způsobilé ke studiu | 1 Year Na 1 Year |
| Pohlaví způsobilá ke studiu | All |
| Přijímá zdravé dobrovolníky | Ano |
| Kritéria | Inclusion Criteria 1. Children of either sex aged between 1-12 years (inclusive); 2. Evidence of acute (onset <7 days prior to screening visit), prolonged (onset between 7 and 14 days prior to screening visit) or chronic (onset >14 days prior to screening visit) diarrhea. - Acute/Prolonged Diarrhea is defined as at least 3 evacuations of loose or watery stools (stools type 6-7 of Bristol scale) occurring in the 24 hours preceding the screening visit. - Chronic Diarrhea (>14 days duration), defined by passage of loose or watery stools (Bristol score 6 or 7) with or without an increase in frequency of bowel movements; 3. Evidence of mild to moderate dehydration, defined as a score 1-4 in the Clinical Dehydration Scale; 4. Parents/legal guardians availability to fill on a daily basis the electronic daily diary by a smartphone/tablet/laptop. 5. Parents/legal guardians* have given a written informed consent for participation in the study at the time of enrolment or before. The parent/legal guardian should also have agreed to bring the child for the visits scheduled in the protocol and to provide the requested information during the telephonic follow-up visit; 6. Parents/legal guardian able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation (ability to attend all the planned investigation visits according to the time limits included) based on Investigator's judgement. Exclusion Criteria: Exclusion Criteria 1. Children of female sex having started menarche; 2. Evidence of severe dehydration, defined as a score > 4 in the Clinical Dehydration Scale; 3. Known hypersensitivity to any of the components (active ingredients or excipients) of the investigational product; 4. Severely malnourished patients, defined as those patients with body weight < 50% for age; 5. History of immune diseases or conditions known to producing immunodeficiency (AIDS, other congenital immunodeficiency syndromes, anticancer drugs, etc.); 6. For acute/prolonged diarrhea only, patients who have received any of the following treatments within the 2 weeks before the screening/baseline visit: - Drugs with adsorbing properties, e.g. kaolin, pectin, bismuth subsalicylate; - Drugs that modify intestinal secretions, e.g. racecadotril; - Drugs that modify intestinal motility, e.g. opiates such as loperamide, atropine and other anti-cholinergic agents); - Laxatives - Antibiotics 7. History of seizures due to known or unknown causes; 8. Parents/legal guardians' refusal or inability to give written informed consent to participate in the study; 9. Parents/legal guardians who, in the opinion of the Investigator, are unable to fill up the electronic patient diary; 10. Patients who may not be possible to come for the scheduled visits; 11. Patients who have participated in any other clinical trial in the last 3 months prior to the start of the study. |
Výsledek
Primární výsledná opatření
1. Acute (onset <7 days) or Prolonged Diarrhea (onset ≥7 and ≤14 days): Response Rate (RR) measured after 4 treatment days. [Day0 to Day4]
2. Chronic Diarrhea (onset >14 days): Response Rate (RR) measured across the whole treatment period [Day0 to Day28]
Měření sekundárních výsledků
1. Number of episodes of daily watery evacuations [Day0-Day28]
2. Number of unformed stools passed per 24-h interval, after the first dose [Day0-Day28]
3. Number of treatment failures [Day0-Day28]
4. Difference in body weight [Day0-Day28]
5. Frequency and severity of diarrhea associated symptoms [Day0-Day28]
6. Treatment Compliance [Day0-Day28]
7. Proportion of patients requiring other (allowed) treatments [Day0-Day28]
8. Change in results of the Pediatric Quality of Life Questionnaire (PedsQL) [Day0-Day28]
9. Change in results in parent assessment of children Quality of Life (100 mm VAS) [Day0-Day28]
10. Safety and tolerability of the treatment: Incidence of adverse events (AEs) and serious adverse events (SAEs), and rate of study discontinuations due to AEs/SAE; [Day0-Day28]
